Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.

ABSTRACT:

Aims

Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. The impact of switching treatment from another GLP-1 receptor agonist (GLP-1RA) to semaglutide was investigated by analyses of exposure-response models.

Methods

HbA1c and body weight time-course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme. Given the recommended dosing for each GLP-1RA, pharmacokinetic profiles were simulated based on published population pharmacokinetic models and exposure was adjusted by the relative potencies to ensure that model predictions matched the effects observed in clinical trials. After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended-r

SUBMITTER: Overgaard RV 

PROVIDER: S-EPMC6585654 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature